Genelux Corporation

NASDAQ:GNLX

Biotechnology

Healthcare
$2.00 +2.63%

+$0.08 today

Market cap
$90.49M
Beta
0.55
P/E (TTM)
-3.0
EPS (TTM)
-$0.98
52W Low $2.29High $8.54

Volume 0.25M

Average 0.19M

Returns on capital

Genelux Corporation management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-278.5%

avg -51.0%

ROIC

-251.1%

avg -65.3%

ROA

-168.9%

avg -161.5%

Analysis

ROA is currently the strongest return metric at -168.9% versus its period average of -161.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Thomas Zindrick

Chairman, Chief Executive Officer & PresidentUSD 784.16K661.22M3.25%

Matthew Pulisic

Chief Financial Officer and Principal Financial & Accounting OfficerUSD 489.56K42278.91K0.74%

Joseph Cappello

Chief Technical OfficerUSD 470.83K69317.81K0.84%

Yong Yu

Chief Scientific OfficerUSD 242.62K54258.02K0.69%

Eric Groen

General Counsel, Corporate Secretary, Chief Compliance Officer & Head of Business Development—55233.96K0.62%

Ralph Smalling

Vice President & Head of Regulatory Affairs—7167.61K0.18%

Jason Litten

Chief Medical Officer—520<0.01%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 3, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

24

$340,564.62

Net Transaction Value

−$340,564.62

Net selling

Most Active

Zindrick Thomas

5 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 3, 26

Zindrick Thomas

Direct

Sell$6.3K
Nov 3, 26

Cappello Joseph

Direct

Sell$1.4K
Nov 3, 26

Yu Yong

Direct

Sell$1.3K
Aug 31, 26

Zindrick Thomas

Direct

Sell$91.9K
Aug 31, 26

Yu Yong

Direct

Sell$26.7K
Aug 31, 26

Cappello Joseph

Direct

Sell$28.1K
Aug 4, 26

Zindrick Thomas

Direct

Sell$8.9K
Aug 4, 26

Cappello Joseph

Direct

Sell$1.9K
Aug 4, 26

Yu Yong

Direct

Sell$1.9K
Jul 1, 26

Smither John W

Direct

Sell$34.9K

1–10 of 24

Summary

Insiders reported 0 buys worth $0.00 and 24 sells worth $340,564.62 over the last 12 months. That adds up to net selling of $340,564.62. Zindrick Thomas was the most active insider with 5 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A-91.0%
+705.8% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at -91.0% over three years. Forward estimates point to Revenue at +705.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Genelux Corporation compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about GNLX's management, answered from reported figures.

Who manages GNLX?

Genelux Corporation (GNLX) lists 7 active executives. The top listed executive is Thomas Zindrick, Chairman, Chief Executive Officer & President.

Are GNLX insiders buying or selling?

Recent insider activity shows net buying of $2.75M.